Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625827 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06625827 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 24 participants.
The verdict
NCT06625827, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of the study is to learn what happens to levels of digoxin in a healthy person's body over time. Researchers will compare what happens to digoxin in the body when it is given with and without another medicine called nemtabrutinib. Researchers are testing if digoxin levels in the body are different when digoxin is given with or without nemtabrutinib.
Interventions
- DRUG Nemtabrutinib
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625827
The ClinicalTrials.gov registry entry for NCT06625827 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nemtabrutinib is the first listed.
NCT06625827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06625827 about?
NCT06625827 is a clinical study titled "A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)". The goal of the study is to learn what happens to levels of digoxin in a healthy person's body over time. Researchers will compare what happens to digoxin in the body when it is given with and without another medicine called nemtabrutinib. Researchers are testing if digoxin levels in the body are di...
What is the current status of trial NCT06625827?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-11-07. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT06625827?
The interventions under investigation include: Nemtabrutinib (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT06625827?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.